In a closely observed development in the world of gene technology, a Delaware federal judge has ruled against Seattle-based NanoString Technologies Inc. in a patent infringement dispute with competitor 10x Genomics. The judge denied NanoString’s bid to argue that the patent claims are too indefinite be legally protected.
As the latest turn in this high-stakes legal bout, the judge’s decision ensures that this hotly contested patent battle will move forward to a November jury trial. Understandably, the outcomes of such a trial could have potentially far-reaching implications for both companies and for the broader sector.
It is not uncommon for innovation-driven sectors, like gene sequencing, to witness heated patent disputes. Often, the driveway to breakthroughs is paved with numerous legal challenges, concerning the ownership and applicability of cutting-edge technologies. For industry stakeholders, following the course of such disputes becomes crucial as they can conclusively impact both business operations and broader industry trends.
For those closely monitoring this case, additional details can be found on Law360’s article on this matter. Given how these patent battles unfold, the trial in November will definitely provide some compelling legal action to look forward to.